BCFC Introduction This is a very special article, as I discuss a company I have never covered before. As I have been on Seeking Alpha for almost a decade, that doesn't happen very often. As some readers may know, I check the S&P 500's worst performers every day. I do this for the same reason I always check the clearance shelf in stores. You never know when you'll find a bargain! Earlier this month, the McKesson Corporation (NYSE:MCK) stood out, as it saw its stock price decline from $580 to almost $500. ...

The most recent trading session ended with McKesson (MCK) standing at $518.81, reflecting a +1.49% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.72%, and the technology-dominated Nasdaq saw an increase of 0.65%.Heading into today, shares of the prescription drug distributor had lost 6.28% over the past month, lagging the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% in that time.Investors will ...

Company Performance - McKesson's stock closed at $511.17, reflecting a +0.14% change from the previous trading day, which lagged behind the S&P 500's gain of 0.75% [1] - Over the last month, McKesson's shares decreased by 7.67%, underperforming the Medical sector's gain of 3.55% and the S&P 500's gain of 4.03% [1] - The upcoming earnings report is expected to show an EPS of $7.20, a 15.57% increase year-over-year, with quarterly revenue anticipated at $89.57 billion, up 16% from the previous year [1] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $32.11 per share and revenue of $353.29 billion, representing increases of +17.02% and +14.35% respectively from the last year [2] - Recent adjustments to analyst estimates indicate a positive outlook for McKesson's business operations and profitability [2] Valuation Metrics - McKesson has a Forward P/E ratio of 15.9, which is lower than the industry's average Forward P/E of 18.11 [3] - The company has a PEG ratio of 1.18, compared to the average PEG ratio of 1.88 for the Medical - Dental Supplies industry [3] Industry Context - The Medical - Dental Supplies industry ranks in the bottom 31% of all industries, with a current Zacks Industry Rank of 176 [4] - The strength of industry groups is measured by the Zacks Industry Rank, which indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

McKesson Corporation (MCK) has agreed to sell its Rexall and Well.ca businesses, both based in Canada, to Birch Hill Equity Partners, a Canadian private equity firm. The deal supports McKesson's strategic decision to concentrate on expanding its oncology and biopharma services while maintaining its focus on the Canadian healthcare market through distribution and biopharma. Through this transaction, Rexall and Well.ca will benefit from Birch Hill's commitment to investing in growth and expanding services acr ...

Key TakeawaysThe S&P 500 slid 0.3% on Thursday, Sept. 5, with soft private payroll data adding to concerns about the labor market ahead of Friday's jobs report.McKesson shares plunged after the medical products distributor announced plans to sell its Canada-based Rexall and Well.ca businesses.Dollar Tree shares moved higher, clawing back some of the steep losses in the previous session. Major U.S. equities indexes were mixed as the latest ADP jobs data showed a smaller-than-expected jump in private payrolls ...

McKesson Corporation (NYSE:MCK) Wells Fargo 2024 Healthcare Conference September 5, 2024 8:45 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Stephen Baxter - Wells Fargo Stephen Baxter Good morning. I'm Steve Baxter, the Healthcare Services Analyst at Wells Fargo. We're really pleased to have McKesson with us today. As I'm sure you know, McKesson is the largest drug distributor in the United States, also operates Pharma Services ...

Core Viewpoint - McKesson (MCK) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks Consensus Estimate projects McKesson to earn $32.02 per share for the fiscal year ending March 2025, reflecting a year-over-year increase of 16.7% [5]. - Over the past three months, the consensus estimate for McKesson has risen by 1.8%, indicating a trend of increasing earnings estimates [5]. Impact of Earnings Estimates - Changes in a company's earnings potential, as shown by earnings estimate revisions, are strongly correlated with short-term stock price movements [3]. - Institutional investors utilize earnings estimates to assess the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Zacks Rating System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with a proven track record of Zacks Rank 1 stocks yielding an average annual return of +25% since 1988 [4]. - McKesson's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [7].

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about McKesson (MCK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.McKesson currently has an average brokerage recommendation (ABR) ...

McKesson Corporation (MCK) , on Monday, inked a definitive agreement to acquire a controlling interest (representing approximately 70% ownership) in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), subject to customary closing conditions. Florida Cancer Specialists & Research Institute, LLC (“FCS”) physicians will retain a minority interest in Core Ventures.Core Ventures, a business and administrative services organization, was established by FCS.Following the completion of the tr ...

McKesson (MCK) is witnessing strong momentum, with its shares having rallied 18.3% year to date compared with 0.6% growth of the industry. The S&P 500 Composite has risen 16.5% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments — Distributio ...